Rocket Pharmaceuticals, Inc. Common Stock (RCKT) is a publicly traded Healthcare sector company. As of May 21, 2026, RCKT trades at $3.05 with a market cap of $335.22M and a P/E ratio of -1.47. RCKT moved +1.37% today. Year to date, RCKT is -16.34%; over the trailing twelve months it is -56.64%. Its 52-week range spans $2.19 to $18.89. Analyst consensus is buy with an average price target of $9.67. Rallies surfaces RCKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RCKT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RCKT recently traded at $3.05. Market cap is $335.22M. P/E ratio is -1.47. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $3.05 |
| Market Cap | $335.22M |
| P/E Ratio | -1.47 |
| EPS | $-2.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.89 |
| 52-Week Low | $2.19 |
| Volume | 820 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-223.12M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-223.12M | $-2.01 |
| 2023 | $0 | $-245.59M | $-2.92 |
| 2022 | $0 | $-221.86M | $-3.26 |
| 2021 | $0 | $-169.07M | $-2.67 |
13 analysts cover RCKT: 0 strong buy, 7 buy, 4 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.67.